PRODUCT CATEGORY

PRODUCT SEARCH

NEWSLETTER

Register now!Newsletter subscription

  • CATALOG PDF Download
  • BROCHURES PDF Download

Anti CD44 v9 and v10-e16 Antibody References

Citation

cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
Miyano K, Cabral H, Miura Y, Matsumoto Y, Mochida Y, Kinoh H, Iwata C, Nagano O, Saya H, Nishiyama N, Kataoka K, Yamasoba T.
J Control Release. 2017 Sep 10;261:275-286. PMID: 28666729
CD44 variant 9 expression as a predictor for gastric cancer recurrence: immunohistochemical and metabolomic analysis of surgically resected tissues.
Yamakawa Y, Kusuhara M, Terashima M, Kinugasa Y, Sugino T, Abe M, Mochizuki T, Hatakeyama K, Kami K, Yamaguchi K.
Biomed Res. 2017;38(1):41-52. PMID: 28239031
Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression.
Kasai S, Furuichi Y, Ando N, Kagami K, Abe M, Nakane T, Goi K, Inukai T, Saitoh S, Ohno S, Okazaki S, Nagano O, Saya H, Sugita K.
Cell Death Dis. 2017 Jun 1;8(6):e2857. PMID: 28569787
Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.
Miwa T, Nagata T, Kojima H, Sekine S, Okumura T.
Int J Oncol. 2017 Sep;51(3):771-780. PMID: 28677740
CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma.
Kakehashi A, Ishii N, Sugihara E, Gi M, Saya H, Wanibuchi H.
Cancer Sci. 2016 May;107(5):609-18. PMID: 26882440
Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.
Hagiwara M, Kikuchi E, Kosaka T, Mikami S, Saya H, Oya M.
Urol Oncol. 2016 Aug;34(8):337.e19-26 PMID: 27133224
Calreticulin is highly expressed in pancreatic cancer stem-like cells.
Matsukuma S1, Yoshimura K1,2, Ueno T1, Oga A3, Inoue M1,2, Watanabe Y1, Kuramasu A, Fuse M, Tsunedomi R, Nagaoka S, Eguchi H, Matsui H, Shindo Y, Maeda N, Tokuhisa Y, Kawano R, Furuya-Kondo T, Itoh H, Yoshino S, Hazama S, Oka M, Nagano H.
Cancer Sci. 2016 Nov;107(11):1599-1609. PMID: 27561105
Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component.
Umeda T, Ishida M, Murata S, Mori T, Kawai Y, Itoi N, Tomida K, Tanaka A, Sakai S, Kitamura M, Kubota Y, Kushima R, Tani M.
Breast Cancer. 2016 Nov;23(6):869-875. PMID: 26494575
Pancreatic cancer cells express CD44 variant 9 and multidrug resistance protein 1 during mitosis.
Kiuchi S, Ikeshita S, Miyatake Y, Kasahara M.
Exp Mol Pathol. 2015 Feb;98(1):41-6. PMID: 25481101

Reference

Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation.
Yoshida GJ, Saya H.
Biochem Biophys Res Commun. 2014 Jan 10;443(2):622-7. PMID: 24333422
Three-dimensional culture of sebaceous gland cells revealing the role of prostaglandin E2-induced activation of canonical Wnt signaling.
Yoshida GJ, Saya H, Zouboulis CC.
Biochem Biophys Res Commun. 2013 Sep 6;438(4):640-6. PMID: 23948691
xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.
Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O.
Cancer Res. 2013 Mar 15;73(6):1855-66. PMID: 23319806
Redox regulation in stem-like cancer cells by CD44 variant isoforms.
Nagano O, Okazaki S, Saya H.
Oncogene. 2013 Oct 31;32(44):5191-8. PMID: 23334333
Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells.
Masuko K, Okazaki S, Satoh M, Tanaka G, Ikeda T, Torii R, Ueda E, Nakano T, Danbayashi M, Tsuruoka T, Ohno Y, Yagi H, Yabe N, Yoshida H, Tahara T, Kataoka S, Oshino T, Shindo T, Niwa S, Ishimoto T, Baba H, Hashimoto Y, Saya H, Masuko T.
PLoS One. 2012;7(1):e29728. PMID: 22272243
Reactive oxygen species-induced autophagic degradation of Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells.
Tsugawa H, Suzuki H, Saya H, Hatakeyama M, Hirayama T, Hirata K, Nagano O, Matsuzaki J, Hibi T.
Cell Host Microbe. 2012 Dec 13;12(6):764-77. PMID: 23245321
Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell.
Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, Osawa T, Kanki Y, Minami T, Aburatani H, Ohmura M, Kubo A, Suematsu M, Takahashi K, Saya H, Nagano O.
Nat Commun. 2012 Jun 6;3:883. PMID: 22673910
Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein.
Masuko T, Ohno Y, Masuko K, Yagi H, Uejima S, Takechi M, Hashimoto Y.
Cancer Sci. 2011 Jan;102(1):25-35. PMID: 21040216
CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth.
Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H.
Cancer Cell. 2011 Mar 8;19(3):387-400. PMID: 21397861
CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis.
Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, Saya H, Nagano O.
Cancer Sci. 2010 Mar;101(3):673-8. PMID: 20028388
The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases.
Lo M, Wang YZ, Gout PW.
J Cell Physiol. 2008 Jun;215(3):593-602. PMID: 18181196
Identification of pancreatic cancer stem cells.
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM.
Cancer Res. 2007 Feb 1;67(3):1030-7. PMID: 17283135
Phenotypic characterization of human colorectal cancer stem cells.
Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF.
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63. PMID: 17548814
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE.
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8. PMID: 17210912
Prospective identification of tumorigenic prostate cancer stem cells.
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ.
Cancer Res. 2005 Dec 1;65(23):10946-51. PMID: 16322242
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance.
Huang Y, Dai Z, Barbacioru C, Sadee W.
Cancer Res. 2005 Aug 15;65(16):7446-54. PMID: 16103098
CD44: from adhesion molecules to signalling regulators.
Ponta H, Sherman L, Herrlich PA.
Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45. PMID: 12511867
Prospective identification of tumorigenic breast cancer cells.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF.
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8. PMID: 12629218
Expression of CD44R1 adhesion molecule in colon carcinomas and metastases.
Tanabe KK, Ellis LM, Saya H.
Lancet. 1993 Mar 20;341(8847):725-6. PMID: 8095628
CD44 is the principal cell surface receptor for hyaluronate.
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B.
Cell. 1990 Jun 29;61(7):1303-13. PMID: 1694723

Product List

Product Name Cat# Quantity Price

Anti CD44v9

CAC-LKG-M003 50UG

¥ 60,000
$ 800
€ 600

Anti CD44v9

CAC-LKG-M001 100UG

¥ 100,000
$ 1334
€ 1000

Anti CD44v10-e16

CAC-LKG-M002 100UG

¥ 100,000
$ 1334
€ 1000

To be used for research only. DO NOT use for human gene therapy or clinical diagnosis.